It was found that pre-treatment osteosarcoma biopsy samples with positive ERCC1 immunohistochemistry had worse prognosis both with regard to event free and overall survivals, and that those being positive for both ERCC1 and ABCB1 had significantly worse prognosis [79]. The gene discussed is ABCB1; the disease is osteosarcoma.